Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrie De Mutsert

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Plos One|November 17, 2009
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunizationJoost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, et al.
Journal of Virology|November 22, 2013
Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virusCarolien E van de Sandt, Joost H C M Kreijtz, Gerrie de Mutsert, et al.
The Journal of General Virology|August 20, 2010
Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret modelJoost H C M Kreijtz, Yasemin Süzer, Rogier Bodewes, et al.
The Lancet. Infectious Diseases|December 3, 2014
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialJoost H C M Kreijtz, Marco Goeijenbier, Fleur M Moesker, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Plos One|November 17, 2009
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunizationJoost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, et al.
Journal of Virology|November 22, 2013
Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virusCarolien E van de Sandt, Joost H C M Kreijtz, Gerrie de Mutsert, et al.
The Journal of General Virology|August 20, 2010
Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret modelJoost H C M Kreijtz, Yasemin Süzer, Rogier Bodewes, et al.
The Lancet. Infectious Diseases|December 3, 2014
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialJoost H C M Kreijtz, Marco Goeijenbier, Fleur M Moesker, et al.
Pageof 2